Soluble Aβ pathology predicts neurodegeneration and cognitive decline independently on p‐tau in the earliest Alzheimer's <i>continuum</i> : Evidence across two independent cohorts

We assessed brain atrophy and cognitive decline in asymptomatic individuals. Aβ biomarkers predicted MTL atrophy independently of p-tau. Our results underscore the importance of undertaking Alzheimer's preclinical trials.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-02-01
DOI
https://doi.org/10.1002/alz.14415
Citations
8
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
9.31

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Soluble Aβ pathology predicts neurodegeneration and cognitive decline independently on p‐tau in the earliest Alzheimer's continuum : Evidence across two independent cohorts

Karine Fauria, Gonzalo Sánchez Benavides, Luigi Lorenzini, Carles Falcón et al.
8 citations
Alzheimer s & Dementia
Alzheimer's disease research and treatments
9.31
article

Soluble Aβ pathology predicts neurodegeneration and cognitive decline independently on p‐tau in the earliest Alzheimer's continuum : Evidence across two independent cohorts

Karine Fauria, Gonzalo Sánchez Benavides, Luigi Lorenzini, Carles Falcón, Anna Brugulat‐Serrat, José Luís Molinuevo, Marc Suárez Calvet, Silvia Ingala, Raffaele Cacciaglia, Frederik Barkhof, Juan Domingo Gispert, Alle Meije Wink, Karen A. Ritchie, Gwendlyn Kollmorgen, Kaj Blennow, Carolina Minguillón, Clara Quijano‐Rubio, Henrik Zetterberg, Marta Milà Alomà
article en
8 citations

Abstract

We assessed brain atrophy and cognitive decline in asymptomatic individuals. Aβ biomarkers predicted MTL atrophy independently of p-tau. Our results underscore the importance of undertaking Alzheimer's preclinical trials.

Alzheimer s & DementiaVol. 21(2)
Roche (Switzerland) (CH), University of Wisconsin–Madison (US), Universitat Pompeu Fabra (ES), Sahlgrenska University Hospital (SE), Roche Pharma AG (Germany) (DE), Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (ES), Pasqual Maragall Foundation (ES), UK Dementia Research Institute (GB), Barcelonaβeta Brain Research Center (ES), Hospital Del Mar (ES), Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (ES), National Hospital for Neurology and Neurosurgery (GB), Amsterdam University Medical Centers (NL), Global Brain Health Institute (US), Northern California Institute for Research and Education (US), University College London (GB), Vrije Universiteit Amsterdam (NL), University of Gothenburg (SE), University of Edinburgh (GB)
Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Familjen Erling-Perssons Stiftelse, Stiftelsen för Gamla Tjänarinnor, EU Joint Programme – Neurodegenerative Disease Research, Ministerio de Ciencia, Innovación y Universidades, University College London, European Commission, Hjärnfonden, Vetenskapsrådet, UK Dementia Research Institute, Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona, National Institutes of Health, HORIZON EUROPE Framework Programme, Instituto de Salud Carlos III, Agencia Estatal de Investigación
Quality Education
Openalex Percentile: Top 2%
Alzheimer's disease research and treatments
9.31
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.